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INTRODUCTION
Since laparoscopic gastrectomy (LG) for gastric cancer was in-
troduced by Kitano et al. in 1994, the number of patients undergo-
ing LG for gastric cancer has continued to increase rapidly (1).
LG has four major advantages when compared with conventional
open gastrectomy (OG) : 1) less intra-operative blood loss, 2) less
post-operative pain, 3) less respiratory dysfunction, and 4) shorter
hospital stays (2, 3). In Japan, patients with early gastric T1N0
cancer, which is characterized by invasion of the mucosa and sub-
mucosa and the absence of lymph node metastasis, have under
gone LG with D1 or D1+ lymph node dissection. Recently, LG with
extended lymph node dissection (D2) has been the prevailing treat-
ment for advanced gastric cancer in some institutions (4). However,
the Gastric Cancer Treatment Guidelines (3rd edition) state that
indications for LG should be determined following additional clini-
cal trials involving randomized control studies (5). Therefore, LG
for advanced gastric cancer remains controversial.
Notably, a case involving port -site recurrence after LG (7). There-
fore, indicators of disease recurrence after LG remain unclear
because laparoscopic surgery has specific recurrences that are
different than open gastrectomy (OG). The aim of this study was
to identify risk factors for disease recurrence following LG and
compared these risks with those identified for OG.
PATIENTS AND METHODS
From January 2004 through December 2010, 212 patients (132
men, 80 women ; mean age 68 years ; age range 35-91 years) were
referred to our institution for treatment of gastric cancer. To match
the backgrounds of the patients in the LG group with those of
patients in the OG group, the OG group included only patients with
fStage I or II cancer.
Eligibility criteria for laparoscopic versus open surgery
Of the 212 patients, 143 (85 men, 58 women ; mean age=66
years ; age range=40-89 years) underwent laparoscopic proce-
dures. Written informed consent was provided by each patient
before surgery. LG with D1 or D1+ lymph node dissection were
performed for clinical stage IA cancers ; LAG with D2 dissection
were performed for stage IB (T2N0) cancers ; all cancer staging
was based on the Japanese Gastric Cancer Treatment Guidelines
2010 (5). Of the 212 patients, 69 (47 men, 22 women ; mean age=72
years ; age range=35-91 years) underwent OG (Table 1). OG with
D1 or D1+ or OG with D2 were performed for cases involving clini-
cal stage IB (T1N1) or stage II cancers or for cases in which LG was
not indicated fornon-oncological reasons.
Lymph node dissection strategy of LAG
In the Japanese Gastric Cancer Treatment Guidelines 2010 (5),
LG has been categorized as appropriate for clinical trials in cases
involving clinical stage IA or IB cancers. Therefore, according to
the treatment plan, LG with lymph node dissection (D1 or D1+)
was performed for T1N0 disease and LG with lymph node dissec-
tion (D2) was performed for cT2N0 disease. However, limited lymph
node dissection was performed for the elderly patients or patients
with severe comorbidities. All cancer staging was based on the
Japanese Classification of Gastric Carcinoma (JCGC) (3rd English
edition, corresponds to the Japanese 14th edition)(6).
Parameters
General clinical and clinicopathological data from each eligible
patient were retrieved from medical reports ; all data was reviewed
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retrospectively. LG and OG groups were compared with regard
to six variables, pathological stage (which was based on JCGC
staging), operative procedures, extent of lymph node dissection,
number of dissected lymph nodes, postoperative morbidities, and
postoperative mortalities.
Evaluation of curability
The JCGC staging and the gastric cancer clinical practice guide-
lines of the National Comprehensive Cancer Network (NCCN) both
define three criteria used to determine whether a gastric cancer
indicates curative resection : 1) no involvement of the proximal
and distal margins, 2) proximal and distal distances of no less than
10 mm, and 3) sufficient lymph node dissection with no fewer than
15 lymph nodes dissected (7). Each eligible patient was evaluated
using these criteria. The LG and OG groups were compared with
regard to recurrence site and long-term disease- free survival
(DFS).
Follow-up schedule
Follow-ups were scheduled on a 6-month basis for 10 years ;
each follow-up included a clinical examination ; monitoring of se-
rum CEA, CA19-9, and CA125 cancer antigen levels ; endoscopy ;
abdominal CT scan ; or some combination thereof.
Statistical analysis
The unpaired Student’s t - test or the Mann-Whitney U test was
used statistical analysis of continuous variables ; the χ2 test was
used for categorical variables. For all three tests, p0.05 was in-
terpreted as significant. Values for each continuous variable are
expressed as a meanthe standard deviation (SD). Long-term
prognosis was determined by the Kaplan-Meier method using
JMP 8 software (SAS Institute, Cary, NC, USA). The log-rank test
was used to assess the significance of differences in DFS between
the LG and OG groups.
RESULTS
The clinicopathological characteristics of patients in the LG and
OG groups are shown in Table 1. The percentage of D1 and D1+
lymph node dissections was higher for the LG group than the OG
group. Similarly the percentage of cases involving T1 cancers,
which invaded only the mucosa or submucosa, but no venous in-
vasion, was higher for the LG group than the OG group.
DFS following LG and risk factors for disease recurrence fol-
lowing LG
A comparison between cStage (clinical Stage) and fStage (final
Stage) cancers is presented in Table 2. Indications for LG were
limited to cT2 and cN0 cancers, which invaded only up to the mu-
cosal plate and did not involve lymph node metastasis ; therefore,
the proportion of IA and IB cancers among the cStage cancers was
71.3% and 28.7%, respectively. Among fStage cancers, the propor-
tions of IA, IB, IIA, IIB, and IIIA were 74.1%, 16.1%, 6.3%, 1.4%, and
2.1%, respectively. The proportion of overdiagnosis (fStage II)
was 9.8%.
The 5-year OS and DFS rates for the LG were 94.1% and 91.4%,
respectively (Figures 1a and 1b). Based on univariate analyses,
four factors- lymph node metastasis, JGCA stage, lymphatic inva-
sion, and venous invasion-were each significant negative indica-
tors for DFS in LG (Table 3). The rate of recurrence after LG was
higher for cancers with more lymph node metastases (recurrence
rate ; fN0 1.7%, fN1 14.3%, fN225%, data not shown). Based on a
multivariate analysis, the only independent risk factor for disease
recurrence after LG was fN (+) (Table4).
Sites of recurrence and DFS following LG or OG
The recurrence rates in the LG and OG groups were 4% and 9%,
respectively, and this difference was statistically significant (p
0.05). Among the 143 patients who underwent LG, two developed
post-operative liver metastasis, and four developed peritoneal dis-
seminations. Neither port -site recurrence nor lymph node metas-
tasis was observed (data not shown).
DFS following LG was significantly better than that following OG
(5-year-DFS ; LG 91.4% vs. OG 77.5%, p0.01) (Figure 2). Among
the cases involving fStage cancers, 5 -year DFS following resection




Age (median) 40-89 (66) 35-91 (72) N.S.
Gender : male/female 85/58 47/22 N.S.
Gastrectomy : Distal/Total/Proximal/Other 107/33/1/2 31/31/1/6 N.S.
Lymph node dissection : D1,D1+/2 113/30 32/37 0.05
Number of dissected lymph nodes (Median) 25 27 N.S.
Differentiation :
Differentiation/Undifferentiation 88/55 40/29 N.S
fT (T1/T2/T3) 120/21/2 33/32/4 0.05
fN (N(-)/N(+)) 118/25 50/19 N.S.
fStage (I/II/III) 129/11/3 50/19/0 N.S.
ly (+/-) 42/101 27/42 N.S.
v (+/-) 16/127 25/44 0.05
Table 2. Comparison between cStage and fStage in LG
Stage cStage (n=143) fStage (n=143)
IA 102 (71.3%) 106 (74.1%)
IB 41 (28.7%) 23 (16.1%)
IIA 0 (0%) 9 (6.3%)
IIB 0 (0%) 2 (1.4%)
IIIA 0 (0%) 3 (2.1%)
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of fStage IA, IB, or II cancers was not different between the LG and
OG groups (LG vs. OG ; IA 97.8% vs. 100%, IB 75.6% vs. 84.9%, II
79.5% vs. 43.1%) (Figure 3a, b, c).
The univariate analysis of DFS for all 212 cases (LG and OG) is
presented in Table 5. Differentiation, tumor invasion, lymph node
metastasis, stage, lymphatic and venous invasion, approach were
each significant factors for DFS. The multivariate analysis found
that tumor invasion and lymph node metastasis were each inde-
pendent risk factors for disease recurrence following LG (Table 6).
OG, which was identified as a significant prognostic factor in the
univariate analysis, was not an independent risk factor for recur-
rence based on the multivariate analysis.
Figure 1a, b : OS and DFS curves for the LG group.
Table 3. Univariate analysis of 5 -year DFS in LG.
Factors 5 -year DFS (%) p value
Age (65/65) 95.4/85.8 0.26
Gender (male/female) 95.5/82.5 0.44
Lymph node dissection (D1, D1+/D2) 95.6/74.2 0.05
Differentiation :
(Differentiation/Undifferentiation) 95.4/87.0 0.65
fT (T1/T2) 93.3/84.6 0.05
fN (-/+) 96.8/63.3 0.01
fStage (I/II, III) 94.0/75.0 0.01
ly (-/+) 97.7/77.4 0.01
v (-/+) 92.8/83.1 0.05
Table 4. Multivariate analysis of 5 -year DFS in LG.
Factors HR (95%CI) p value
Age (65) 3.009 (0.490-18.47) 0.72
Gender (female) 0.680 (0.083-5.606) 0.68
Lymph node dissection (D2) 0.961 (0.097-9.490) 0.97
Differentiation (Undifferentiation) 0.727 (0.091-5.814) 0.76
fT (fT2) 2.387 (0.323-17.62) 0.39
fN (+) 6.277 (0.700-56.29) 0.05
Figure 2 : Respective DFS curves for the LG and OG groups.
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Figure 3a, b, c : DFS curves of LG and OG according to fStage.
Table 5. Univariate analysis of 5 -year DFS in all cases (LG and OG).
Factors 5 -year DFS (%) p value
Age (65/65) 87.2/77.7 0.19
Gender (male/female) 82.2/82.7 0.29
Lymph node dissection (D1, D1+/D2) 82.2/75.9 0.67
Differentiation :
(Differentiation/Undifferentiation) 91.3/73.6 0.05
fT (T1/T2) 93.5/65.7 0.01
fN (-/+) 93.4/59.5 0.01
fStage (I/II, III) 93.3/53.0 0.01
ly (-/+) 94.4/64.3 0.01
v (-/+) 90.0/60.3 0.01
Approach (LG/OG) 91.4/69.0 0.01
Table 6. Multivariate analysis of 5 -year DFS in all cases (LG and OG).
Factors HR (95%CI) p value
Age (65) 1.871 (0.772-4.537) 0.17
Gender (female) 1.787 (0.683-4.673) 0.24
Lymph node dissection (D2) 2.208 (0.780-6.250) 0.14
Differentiation (Undifferentiation) 2.208 (0.875-5.574) 0.09
fT (fT2) 5.170 (1.476-18.11) 0.05
fN (+) 4.187 (0.695-11.25) 0.01
Approach (OG) 2.171 (0.695-6.781) 0.18
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DISCUSSION
This study was designed to investigate the risk factors for dis-
ease recurrence after curative LG for gastric cancer. In the LG
group, the 5-year OS was 94.1% ; DFS was 91.4% ; the recurrence
rate was 3%, and the sites of recurrence were liver (n=2) and peri-
toneum (n=4). In the entire group of 212 consecutive patients,
neither port -site nor lymph-node recurrence were observed. Based
on a univariate analysis of data from 143 patients who underwent
curative LG, lymph node metastasis, lymphatic and venous inva-
sion were each significant negative prognostic factors. Further-
more, lymph node metastasis was identified as an independent risk
factor for recurrence. DFS in LG was comparable to that in OG of
the same fStage. Among all patients who underwent gastrectomy
(LG or OG),fT2 and fN (+) were each independent risk factors
for disease recurrence. A laparoscopic approach was not an inde-
pendent risk factor for recurrence. However, the limitation of this
study was totally retrospective study.
Based on several studies that included randomized controlled
trials, LAG with D1/D1+ lymph node dissection results in accept-
able short - and long-term outcomes when used as a treatment for
early gastric cancer (9-14).
Nevertheless, LAG with D2 lymph node dissection has not been
recognized as a standard surgical option for advanced gastric can-
cer. Hamabe et al. reported that LG with D2 lymph node dissection
was acceptable in terms of long-term results for advanced gastric
cancer cases (15). At our institution, LG with D2 lymph node dis-
section has been performed for T2N0 gastric cancer. Based on an
analysis of the fStage cancers in our series, the LG and OG groups
did not differ significantly with regard to 5-year DFS. If the diffi-
culty of D2 lymph node dissection can be overcome, LG will be the
indicated surgical option for treatment of advanced gastric cancer.
In our study, fN(+) was identified as an independent risk factor
for disease recurrence after LG ; notably, fN(+) was also an inde-
pendent risk factor following OG. T stage and N stage are each
reportedly independent risk factors for disease recurrence after
LG (16). Lee et al. reported that N1-3 in early gastric cancers and
N2,3 in advanced gastric cancers according to lymph node dissec-
tion were the most potent risk factors for disease recurrence after
LG (17). Laparoscopic surgery for gastric cancer has a demonstra-
bly smaller effect than conventional surgery on the inflammatory
factors that have been implicated in local recurrence and peritoneal
metastasis because laparoscopic surgery results in smaller post-
operative immune responses, both in the peritoneum and systemi-
cally (18). In the present study, the recurrence rate after LG was
significantly lower than that after OG. Therefore, laparoscopic sur-
gery for gastric cancer may contribute to the suppression of dis-
ease recurrence after a curative operation when compared with
conventional open surgery.
Limitations of our study were totally retrospective study, and a
selection bias in background of the two groups. Therefore, the
prospective and double blind study will be needed.
In conclusion, the long-term outcomes associated with LG are
acceptable when compared with those of OG. Lymph node metas-
tasis was identified as an independent risk factor for disease re-
currence after LG. Therefore, laparoscopic gastrectomy may be
adaptable to advanced gastric cancer with no preoperative indica-
tion of lymph node metastasis.
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